Beli Company Overview, Contact Details & Competitors

Insights

Gathering insights about Beli…

Similar companies to Beli

Beli Tech Stack

Beli uses 8 technology products and services including Drupal, Neo4j, OpenStack, and more. Explore Beli's tech stack below.

Drupal
Content Management System
Neo4j
Database
OpenStack
Infrastructure As A Service
Juniper Networks
IT Infrastructure & Operations Management
Weights & Biases
Machine Learning
Brocade
Network Hardware
Solaris
Operating Systems & Computing Languages
Hadoop
Programming Languages

Media & News

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
TAIPEI CITY, Taiwan, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Lin BioScience (6696. Taiwan OTC), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting acute leukemia that have significant unmet medical needs, today announced that its lead pipeline, LBS-007, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. Lin BioScience is currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan, and has been granted for orphan drug designation (ODD) for acute myeloid leukemia and acute lymphocytic leukemia by the U.S. FDA.
Nov 27, 2024 | www.globenewswire.com
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim – Cantor Yi Chen - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Hello, and thank you for joining us to discuss Belite Bio's Third Quarter 2024 Financial Results.
Nov 12, 2024 | seekingalpha.com
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the third quarter ended September 30, 2024.
Nov 05, 2024 | www.globenewswire.com
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes.
Nov 03, 2024 | www.globenewswire.com
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant.
Sep 01, 2024 | www.globenewswire.com
Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Yi Chen - H.C. Wainwright Bruce Jackson - Benchmark Operator Hello, and thank you for joining us to discuss Belite Bio's Second Quarter 2024 Financial Results.
Aug 12, 2024 | seekingalpha.com
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2024, and provided a general business update.
Aug 09, 2024 | www.globenewswire.com

Beli's Email Address Formats

Beli uses at least 1 format(s):

Beli Email Formats	Example	Percentage
FLast@apple.com	JDoe@apple.com	67%
First.Last@apple.com	John.Doe@apple.com	19%
First_Last@apple.com	John_Doe@apple.com	10%
F.Last@apple.com	J.Doe@apple.com	4%

Frequently Asked Questions

Where is Beli's headquarters located?

Beli's main headquarters is located at New York, NY 10010 US. The company has employees across 2 continents, including North AmericaAsia.

What is Beli's stock symbol?

Beli is a publicly traded company; the company's stock symbol is BLTE.

What is Beli's official website and social media links?

Beli's official website is apple.com and has social profiles on LinkedIn.

How much revenue does Beli generate?

As of November 2024, Beli's annual revenue reached $750K.

What is Beli's SIC code?

Beli's SIC code is 3571 - Electronic Computers.

How many employees does Beli have currently?

As of November 2024, Beli has approximately 18 employees across 2 continents, including North AmericaAsia. Key team members include Head Of Growth: S. B.Co-Founder, Ceo: J. T.Co-Founder, Cto: E. F.. Explore Beli's employee directory with LeadIQ.

What industry does Beli belong to?

Beli operates in the Technology, Information and Internet industry.

What technology does Beli use?

Beli's tech stack includes DrupalNeo4jOpenStackJuniper NetworksWeights & BiasesBrocadeSolarisHadoop.

What is Beli's email format?

Beli's email format typically follows the pattern of . Find more Beli email formats with LeadIQ.

How much funding has Beli raised to date?

As of November 2024, Beli has raised $1,000,000T in funding. The last funding round occurred on Aug 17, 2021 for $1B.

When was Beli founded?

Beli was founded in 2021.

Insights

Similar companies to Beli

Ruby Love

Flamingo

FLO

Knix

Dear Kate

Ruby Cup

Beli Tech Stack

Media & News

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Beli's Email Address Formats

Frequently Asked Questions

Where is Beli's headquarters located?

What is Beli's stock symbol?

What is Beli's official website and social media links?

How much revenue does Beli generate?

What is Beli's SIC code?

How many employees does Beli have currently?

What industry does Beli belong to?

What technology does Beli use?

What is Beli's email format?

How much funding has Beli raised to date?

When was Beli founded?

Beli

Company Overview

Media & News

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?